StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Viking Therapeutics cash

Cash and short-term investments held at the end of each period.

Viking Therapeutics's cash was $959.81M at Sep 30, 2026. For fiscal 2025 it was $705.74M, down 21.8% from the year before. Over ten years it grew 97.8% a year on average. The highest annual figure on record is $902.61M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$705.74M-21.8%
FY2024Dec 31, 2024$902.61M+149.3%
FY2023Dec 31, 2023$362.08M+132.9%
FY2022Dec 31, 2022$155.49M-23.1%
FY2021Dec 31, 2021$202.10M-18.6%
FY2020Dec 31, 2020$248.39M-9.9%
FY2019Dec 31, 2019$275.64M-8.6%
FY2018Dec 31, 2018$301.52M+1365.5%
FY2017Dec 31, 2017$20.58M+568.9%
FY2016Dec 31, 2016$3.08M+300.2%
FY2015Dec 31, 2015$768.55K+1.7%
FY2014Dec 31, 2014$755.86K+320.8%
FY2013Dec 31, 2013$179.62K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$959.81M+34.3%
Q2 FY2026Jun 30, 2026$501.66M-37.9%
Q1 FY2026Mar 31, 2026$602.96M-29.2%
Q4 FY2025Dec 31, 2025$705.74M-21.8%
Q3 FY2025Sep 30, 2025$714.57M-23.2%
Q2 FY2025Jun 30, 2025$807.72M-14.3%
Q1 FY2025Mar 31, 2025$851.86M-11.5%
Q4 FY2024Dec 31, 2024$902.61M+149.3%
Q3 FY2024Sep 30, 2024$930.44M+147.3%
Q2 FY2024Jun 30, 2024$942.26M+139.8%
Q1 FY2024Mar 31, 2024$962.98M+609.8%
Q4 FY2023Dec 31, 2023$362.08M+132.9%
Q3 FY2023Sep 30, 2023$376.24M+142.7%
Q2 FY2023Jun 30, 2023$392.92M+132.6%
Q1 FY2023Mar 31, 2023$135.66M-26.6%
Q4 FY2022Dec 31, 2022$155.49M-23.1%
Q3 FY2022Sep 30, 2022$155.02M-28.3%
Q2 FY2022Jun 30, 2022$168.92M-26.0%
Q1 FY2022Mar 31, 2022$184.90M-23.5%
Q4 FY2021Dec 31, 2021$202.10M-18.6%
Q3 FY2021Sep 30, 2021$216.14M-15.3%
Q2 FY2021Jun 30, 2021$228.26M-13.2%
Q1 FY2021Mar 31, 2021$241.68M-10.2%
Q4 FY2020Dec 31, 2020$248.39M-9.9%
Q3 FY2020Sep 30, 2020$255.30M-11.4%
Q2 FY2020Jun 30, 2020$263.00M-10.1%
Q1 FY2020Mar 31, 2020$269.16M-9.9%
Q4 FY2019Dec 31, 2019$275.64M-8.6%
Q3 FY2019Sep 30, 2019$288.07M-5.3%
Q2 FY2019Jun 30, 2019$292.64M+745.5%
Q1 FY2019Mar 31, 2019$298.72M+721.6%
Q4 FY2018Dec 31, 2018$301.52M+1365.5%
Q3 FY2018Sep 30, 2018$304.16M+11744.3%
Q2 FY2018Jun 30, 2018$34.61M+919.7%
Q1 FY2018Mar 31, 2018$36.36M+734.0%
Q4 FY2017Dec 31, 2017$20.58M+568.9%
Q3 FY2017Sep 30, 2017$2.57M–
Q2 FY2017Jun 30, 2017$3.39M–
Q1 FY2017Mar 31, 2017$4.36M–
Q4 FY2016Dec 31, 2016$3.08M–

More Viking Therapeutics figures

See a number that looks wrong?